Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Lancet (London, England)
|
December 14, 2020
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
Reuben Benjamin, Charlotte Graham, Deborah Yallop, et al.
Toxicology Reports
|
May 14, 2019
Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3
Laura Tornatore, Daria Capece, Daniel D'Andrea, et al.
The Journal of Clinical Investigation
|
May 23, 2023
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
Benedetta Apollonio, Filomena Spada, Nedyalko Petrov, et al.
The Lancet. Oncology
|
September 17, 2023
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
Niels W C J van de Donk, Monique C Minnema, Bronno van der Holt, et al.
Leukemia
|
March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Maria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
British Journal of Cancer
|
August 17, 2021
Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London
Beth Russell, Charlotte L Moss, Vallari Shah, et al.
American Journal of Hematology
|
March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Holger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.
Blood
|
August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.
American Journal of Hematology
|
June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
Shambavi Richard, Ajai Chari, Sosana Delimpasi, et al.
Blood
|
June 10, 2023
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Kai Rejeski, Marion Subklewe, Mahmoud Aljurf, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Lancet (London, England)
|
December 14, 2020
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
Reuben Benjamin, Charlotte Graham, Deborah Yallop, et al.
Toxicology Reports
|
May 14, 2019
Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3
Laura Tornatore, Daria Capece, Daniel D'Andrea, et al.
The Journal of Clinical Investigation
|
May 23, 2023
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
Benedetta Apollonio, Filomena Spada, Nedyalko Petrov, et al.
The Lancet. Oncology
|
September 17, 2023
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
Niels W C J van de Donk, Monique C Minnema, Bronno van der Holt, et al.
Leukemia
|
March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Maria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
British Journal of Cancer
|
August 17, 2021
Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London
Beth Russell, Charlotte L Moss, Vallari Shah, et al.
American Journal of Hematology
|
March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Holger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.
Blood
|
August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.
American Journal of Hematology
|
June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
Shambavi Richard, Ajai Chari, Sosana Delimpasi, et al.
Blood
|
June 10, 2023
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Kai Rejeski, Marion Subklewe, Mahmoud Aljurf, et al.
Page
of 5